Effect of Sleep Duration Manipulation on Brain-Derived Neurotrophic Factor in Adolescents at Risk for Type 2 Diabetes: A Randomized Crossover Study.

J Sleep ResMay 26, 2026 (epub)
Clinical ResearchEndocrinologyPediatrics

Caroline Dutil, Irina Podinic, Jeremy J Walsh et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized crossover study investigated the impact of sleep duration manipulation on serum brain-derived neurotrophic factor (BDNF) levels in adolescents at risk for type 2 diabetes. The study involved 36 participants who increased and decreased their sleep duration by 1.5 hours for one week each. Increasing sleep duration led to a significant decrease in serum BDNF levels by approximately 14% compared to habitual and decreased sleep conditions.

Key findings

  • Increasing sleep duration resulted in a significant decrease in serum BDNF levels by ~14%.
  • Participants successfully increased sleep duration by +1:02 h/night and decreased it by -1:19 h/night.
  • No significant differences in BDNF levels were observed between habitual and decreased sleep weeks.

Why it matters

Understanding the relationship between sleep duration and BDNF levels in adolescents at risk for type 2 diabetes is crucial, as it may inform strategies to improve metabolic health and manage obesity-related risks in this population.

Source

PubMed · PMID 42192565

Published in J Sleep Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.